Navigation Links
PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryx's Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
Date:6/1/2009

cts receive Traficet-EN. Patients who achieve a pre-specified reduction in disease severity are re-randomized to active drug or placebo for an additional 36-week 'Maintenance Period', thereby permitting an evaluation of the drug's ability to maintain a treatment response.

Traficet-EN is an orally-active inhibitor of the chemokine receptor known as 'CCR9', which is selectively expressed by inflammatory T cells to migrate to the digestive tract in a process that ultimately results in the persistent inflammation underlying the disease. Targeting the CCR9 chemokine receptor represents a novel approach for the treatment of Crohn's disease and other inflammatory disorders of the gastrointestinal system.

About Traficet-EN(TM) (CCX282-B)

Traficet-EN is a small molecule, orally-available drug that is administered in capsule form and which is believed to control the inappropriate immune system response underlying inflammatory bowel disease (IBD) by blocking the CCR9 chemokine receptor. In adults, CCR9 is a highly specific receptor expressed by T cells that migrate selectively to the digestive tract. The trafficking of T cells to the small and large intestine causes persistent inflammation that may result in Crohn's disease or ulcerative colitis - the two principal forms of IBD. In preclinical studies, the compound worked both therapeutically and prophylactically in models of Crohn's disease and ulcerative colitis. In addition to the ongoing PROTECT-1 clinical trial in Crohn's disease, Traficet-EN is being evaluated for patients with celiac disease, a sensitivity to gluten and gluten derivatives in which digestive tract T cells are thought to play an important role. ChemoCentryx has completed five Phase I clinical trials and one four-week Phase II Crohn's disease trial of Traficet-EN, demonstrating that the product candidate is well-tolerated and appropriate for once-daily oral dosing. Traficet-EN may offer advantages
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
2. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
3. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
4. Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL)
5. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
6. TNFerade(TM) Phase III Data Presented at ASCO
7. Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
8. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
9. Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
10. Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
11. Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... , Nov. 21, 2014  CytoSorbents Corporation (OTCQB: ... European Union approved CytoSorb® cytokine adsorber to treat ... the Beacon of Light Award at last night,s ... Dr. Phillip Chan , Chief ... honor to be recognized by the New Jersey ...
(Date:11/22/2014)... Statistics released from a number of organizations ... during the holidays, beginning with Thanksgiving eve, which is ... The data, highlighted in an Infographic ... of their annual Sober Days for the Holidays ... drinking and increased rates of DUI injuries and deaths ...
(Date:11/22/2014)... Nov. 21, 2014 Research and Markets  has ... Drug Industry Report, 2014-2017" report to their offering. ... The Chinese recombinant protein drug market has been expanding ... ability and the like. During 2005-2013, sales of recombinant ... a CAGR of 19.1%, and it is projected that ...
Breaking Medicine Technology:CytoSorbents Wins Beacon of Light Award 2CytoSorbents Wins Beacon of Light Award 3CytoSorbents Wins Beacon of Light Award 4Alarming Stats Show Holiday Drinking an Issue for Many 2China Recombinant Protein Drug Industry Report, 2014-2017 2China Recombinant Protein Drug Industry Report, 2014-2017 3
... HASCO Medical, Inc. (OTC Bulletin Board: HASC ... serves patients in Alabama, Florida, and Mississippi, today announced ... subsidiary of HASCO Medical, has signed an agreement with ... of the agreement, SMM will be providing high-end rehabilitation chairs ...
... NEW YORK, Jan. 13, 2011 Reportlinker.com announces ... in its catalogue: Merck & ... http://www.reportlinker.com/p074950/Merck--Co-Inc-PharmaVitae-Profile.html IntroductionThis analysis examines ... Co. in the prescription pharmaceutical sector. The profile ...
Cached Medicine Technology:HASCO Medical Signs Agreement With the State of Alabama 2Reportlinker Adds Merck & Co., Inc.: PharmaVitae Profile 2
(Date:11/24/2014)... 2014 The Healthy Skin Care Journal, ... affordable skin care products, recently announced its launch. Located ... a wide variety of articles, tips, and evaluations about ... skincare alternatives. , According to Emily Lataille, the website’s ... includes thoroughly researched reviews, tips for the skin, and ...
(Date:11/24/2014)... Alexandria, VA (PRWEB) November 24, 2014 ... will hold its 12th annual International Symposium on Malignant ... in Bethesda, Maryland. Daytime conference sessions will take place ... in Bethesda, while dinners, including a community dinner and ... Regency Bethesda. , Sessions will cover a range of ...
(Date:11/24/2014)... November 24, 2014 Abington Health ... MD has joined The Neurology Group and has ... Sclerosis Center. , A graduate of Vinnica Medical ... at Albert Einstein Medical Center in Philadelphia and completed ... Multiple Sclerosis Center at Weill Cornell Medical College. Ternopolska ...
(Date:11/24/2014)... A new sports massage technique available ... and massage therapy provider, announced it newest massage ... newest sports massage is a fast-acting, “to-the-point” ... sports massage and ESM is that ESM has ... "reset button,” and ESM can increase flexibility, elasticity, ...
(Date:11/24/2014)... November 24, 2014 Recently, SweetDressy.com, a ... unveiled its new collection of 2014 Evening Dresses. All ... According to the company’s marketing manager, the special offer ... for more. , Sweetdressy.com has been working well ... to unveil the latest designs. Their new dresses may ...
Breaking Medicine News(10 mins):Health News:Skin Care Advice Blog The Healthy Skin Care Journal Now Accessible to the Public 2Health News:2015 International Symposium on Malignant Mesothelioma Will Take Place at the National Institutes of Health Campus 2Health News:2015 International Symposium on Malignant Mesothelioma Will Take Place at the National Institutes of Health Campus 3Health News:Nataliya Ternopolska Named Associate Medical Director of Abington Health’s Multiple Sclerosis Center 2Health News:Sports Massage in London by Massaggi Presents New Technique to Reset Muscles, Rapidly Eliminate Pain 2Health News:Sports Massage in London by Massaggi Presents New Technique to Reset Muscles, Rapidly Eliminate Pain 3Health News:SweetDressy.com Unveiled A New Selection Of Evening Dresses 2
... able to delay the onset of the disease or even ... to a study presented today at the annual meeting of ... the results of our study, participating in a high-impact activity, ... least three times a week appears associated with more degenerated ...
... CHICAGO Women with a personal history of breast ... to mammography, according to a study presented today at ... America (RSNA). The American Cancer Society (ACS) guidelines ... with a known gene mutation or with a strong ...
... Institute of Neurological Disease (GIND) in San Francisco have ... a mouse model of Alzheimer,s disease (AD). Humans with ... have abnormally low levels of an enzyme called EphB2 ... in such mice by gene therapy completely fixed their ...
... , SUNDAY, Nov. 28 (HealthDay News) -- The contents of ... nutrition, a new study shows. U.S. researchers examined the ... of 5,930 students at 152 schools. The vending machines in ... value, including chips, sodas and sweets. In elementary schools ...
... , FRIDAY, Nov. 26 (HealthDay News) -- There are a ... Friday," says a University of Delaware researcher. Black Friday, ... holiday shopping season. "If people put a lot of ... who were likely to be the misbehavers on Black Friday," ...
... FRIDAY, Nov. 26 (HealthDay News) -- If you,re told that ... reaction and carefully consider the situation, advises an expert. ... temptation to respond defensively with ,not my child., Understand that ... professor of health services at Saint Joseph,s University in Philadelphia, ...
Cached Medicine News:Health News:Light exercise may prevent osteoarthritis 2Health News:Women with personal history of breast cancer should be screened with MRI 2Health News:Gene therapy prevents memory problems in mice with Alzheimer's disease 2Health News:Parents of Bullies Urged to Open Lines of Communication 2
Inquire...
... CLOtest Rapid Urease Test is recognized by ... urease tests because of its accuracy, convenience ... Marshall, MD. who, along with Robin Warren, ... correlation between H. pylori and gastric ulcers. ...
Serim PyloriTek Test Kit detects urease activity in gastric biopsy specimens for the presumptive identification of an Helicobacter pylori infection....
... The QuickVue H.pylori gII test is a ... qualitative detection of IgG antibodies specific to ... whole blood. It utilizes a convenient, non-invasive, ... aid physicians in the diagnosis of H.pylori ...
Medicine Products: